Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
| Tracking Information | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | July 19, 2007 | ||||||||||||||||||||
| Last Updated Date | September 1, 2011 | ||||||||||||||||||||
| Start Date ICMJE | December 2006 | ||||||||||||||||||||
| Primary Completion Date | December 2010 (final data collection date for primary outcome measure) | ||||||||||||||||||||
| Current Primary Outcome Measures ICMJE |
Day-100 incidence of non-relapse mortality [ Time Frame: 100 days ] [ Designated as safety issue: Yes ] | ||||||||||||||||||||
| Original Primary Outcome Measures ICMJE |
Day-100 incidence of non-relapse mortality [ Time Frame: 100 days ] | ||||||||||||||||||||
| Change History | Complete list of historical versions of study NCT00504803 on ClinicalTrials.gov Archive Site | ||||||||||||||||||||
| Current Secondary Outcome Measures ICMJE |
1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution [ Time Frame: 365 days ] [ Designated as safety issue: Yes ] | ||||||||||||||||||||
| Original Secondary Outcome Measures ICMJE |
1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Quality and timing of immunologic recon [ Time Frame: 365 days ] | ||||||||||||||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||
| Descriptive Information | |||||||||||||||||||||
| Brief Title ICMJE | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease | ||||||||||||||||||||
| Official Title ICMJE | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study | ||||||||||||||||||||
| Brief Summary | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study |
||||||||||||||||||||
| Detailed Description | Not Provided | ||||||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||||||
| Study Phase | Phase 2 | ||||||||||||||||||||
| Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
||||||||||||||||||||
| Condition ICMJE | Hematological Malignancies | ||||||||||||||||||||
| Intervention ICMJE | Procedure: Mesenchymal stem cell infusion
Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
Other Name: Mesenchymal stem cells |
||||||||||||||||||||
| Study Arm (s) | Experimental: 1
MSC co-infusion with either HLA-mismatched PBSC or cord blood
Intervention: Procedure: Mesenchymal stem cell infusion |
||||||||||||||||||||
| Publications * | Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. Epub 2010 Jan 28. | ||||||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||
| Recruitment Information | |||||||||||||||||||||
| Recruitment Status ICMJE | Completed | ||||||||||||||||||||
| Estimated Enrollment ICMJE | 30 | ||||||||||||||||||||
| Completion Date | December 2010 | ||||||||||||||||||||
| Primary Completion Date | December 2010 (final data collection date for primary outcome measure) | ||||||||||||||||||||
| Eligibility Criteria ICMJE | V.1. Patients V.1.1. Diseases Hematological malignancies confirmed histologically and not rapidly progressing:
V.1.2. Clinical situations
V.1.3. Other inclusion criteria
V.1.4. Exclusion criteria
V.2. PBSC donors V.2.1. Inclusion criteria
V.2.2. Exclusion criteria
V.2.3. HLA matching Related or unrelated donors who have 1-2 HLA mismatches, as either :
V.3. Cord blood unit Banked cord blood units will be used if they fulfill the following criteria:
|
||||||||||||||||||||
| Gender | Both | ||||||||||||||||||||
| Ages | up to 75 Years | ||||||||||||||||||||
| Accepts Healthy Volunteers | Yes | ||||||||||||||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||||||
| Location Countries ICMJE | Belgium | ||||||||||||||||||||
| Administrative Information | |||||||||||||||||||||
| NCT Number ICMJE | NCT00504803 | ||||||||||||||||||||
| Other Study ID Numbers ICMJE | TJB0601 | ||||||||||||||||||||
| Has Data Monitoring Committee | No | ||||||||||||||||||||
| Responsible Party | Yves Beguin, University Hospital of Liege | ||||||||||||||||||||
| Study Sponsor ICMJE | University Hospital of Liege | ||||||||||||||||||||
| Collaborators ICMJE | Not Provided | ||||||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||||||
| Information Provided By | University Hospital of Liege | ||||||||||||||||||||
| Verification Date | September 2011 | ||||||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||||||